• Roche Holding affiliate Flatiron Health expanded its non-small cell lung cancer Panoramic dataset with a specimen-level biomarker data model covering 345,000 patients across early-stage and advanced settings.
• The update adds AI-extracted molecular detail across guideline-recommended markers such as EGFR, KRAS, and ALK, plus a set of emerging biomarkers, aiming to support precision-medicine research at larger scale.
• Flatiron positioned the dataset as suitable for regulator-grade real-world evidence, including studies of treatment sequencing, resistance mechanisms, and external comparator arms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608250900BIZWIRE_USPR_____20260825_BW702439) on August 25, 2026, and is solely responsible for the information contained therein.